AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions: Drug: AZD4635
Drug: Durvalumab
Drug: Oleclumab

First Posted Date: 2019-09-13

Last Posted Date: 2024-04-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 59

Registration Number: NCT04089553

Locations: 🇺🇸
Research Site, Nashville, Tennessee, United States

A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C

First Posted Date: 2019-09-12

Last Posted Date: 2019-11-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 14

Registration Number: NCT04087187

Locations: 🇬🇧
Research Site, London, United Kingdom

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Capivasertib
Drug: Enzalutamide
Drug: Abiraterone

First Posted Date: 2019-09-12

Last Posted Date: 2022-07-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 27

Registration Number: NCT04087174

Locations: 🇪🇸
Research Site, Barcelona, Spain

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Combination Product: Symbicort Turbuhaler
Combination Product: BFF

First Posted Date: 2019-09-04

Last Posted Date: 2022-03-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 35

Registration Number: NCT04078126

Locations: 🇩🇪
Research Site, Landsberg, Germany

Durvalumab Long-Term Safety and Efficacy Study

Phase 4

Completed

Conditions: Solid Tumor

Interventions: Drug: Durvalumab

First Posted Date: 2019-09-04

Last Posted Date: 2024-12-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 163

Registration Number: NCT04078152

Locations: 🇻🇳
Research Site, Hanoi, Vietnam

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers

Phase 1

Completed

Conditions: Smoking Cessation

Interventions: Drug: AZD4041
Drug: Placebo

First Posted Date: 2019-09-03

Last Posted Date: 2024-07-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 48

Registration Number: NCT04076540

Locations: 🇺🇸
Research Site, Austin, Texas, United States

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

Phase 3

Active, not recruiting

Conditions: Untreated Chronic Lymphocytic Leukemia

Interventions: Drug: Acalabrutinib
Drug: Rituximab
Drug: Chlorambucil

First Posted Date: 2019-08-30

Last Posted Date: 2025-04-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 155

Registration Number: NCT04075292

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Post-Authorisation Safety Study of Lesinurad

Withdrawn

Conditions: Gout
Hyperuricemia

Interventions: Drug: Zurampic®

First Posted Date: 2019-08-28

Last Posted Date: 2021-04-19

Lead Sponsor: AstraZeneca

Registration Number: NCT04072471

Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)

Completed

Conditions: Lung Cancer, Biliary Tract Cancer

First Posted Date: 2019-08-28

Last Posted Date: 2025-01-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 712

Registration Number: NCT04068168

Locations: 🇰🇷
Research Site, Yongin-si, Korea, Republic of

A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: AZD7594

First Posted Date: 2019-08-28

Last Posted Date: 2019-12-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 24

Registration Number: NCT04072562

Locations: 🇩🇪
Research Site, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy